India's New Trial Rules Tick Right Boxes, Shed Interim Compensation Clause
Executive Summary
India’s new trial regulations have set competitive approval timelines, provide for local trial exemption in specific instances and also drop a controversial draft clause pertaining to interim compensation payable by sponsors.
You may also be interested in...
India Clinical Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change
Leaders from Novartis, IQVIA and PwC discuss the ground situation for trials in India as regulatory reforms, improved infrastructure and clinical expertise provide opportunities. Potential in areas like orphan diseases and tips for peer Amgen on getting trials going in India were among other highlights.
Parexel Execs On Global Adjustments In The Trial Site Landscape
Senior Parexel executives tell Scrip that disruptions resulting from the Ukraine war and constraints in the US given the backlog in clinical care there could channel more trials to the Asia-Pacific region. They also discuss how things are moving in China, a market where the CRO has long-standing experience, the "conducive" ecosystem in India and issues around trial diversity.